#4516 CLINICAL CHARACTERISTICS OF PATIENTS WITH LUPUS NEPHRITIS CLASS III–V: ANALYSIS OF INTERNATIONAL REAL-WORLD DATA

Abstract Background and Aims Lupus nephritis (LN) is a severe renal manifestation of systemic lupus erythematosus (SLE) that negatively impacts morbidity mortality; however, real-world data for LN scarce. This study describes: the proportion patients with SLE managed by rheumatologists (rheum-managed) nephrologists (neph-managed) class III–V; Safety Estrogens in Erythematosus National Assessment - Disease Activity Index (SELENA-SLEDAI) score ≥8 region; extra-renal organ systems involvement flaring EQ-5D EQ-visual analogue scale (VAS) scores estimated glomerular filtration rate (eGFR). Method Data were drawn from Adelphi Specific Programme, cross-sectional, multi-subscriber survey physicians their consulting conducted April 2021–May 2022 China, Japan, EU5 (France, Germany, Italy, Spain UK) USA. Physicians provided demographic clinical 5–6 consecutive adult SLE/LN. III–V was assessed physician at collection. SELENA-SLEDAI derived assessment patients’ current manifestations. Patients had opportunity to complete an form. All analyses descriptive. Results Overall, 9% (183/2148) rheum- 48% (364/766) neph-managed LN. Most (70% 76% neph-managed; Table 1), compared (1032/2148) rheum-managed alone. The varied region, 58% USA 87% China. In total, 62% 43% ever flared (any system; 1). who ranged 52% China + Japan 75% EU5. currently experiencing flare similar between (31%) (35%) patients, but highest (59%) lowest (18%). subgroups ≥15 EQ-VAS generally worsened as eGFR lowered (Figure Conclusion high disease burden (SELENA-SLEDAI ≥8) suggesting need more efficacious treatments